EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSONIG00000010123
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSONIG00000006001
Gene Symbol: EGLN2
4 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSONIG00000035400
Gene Symbol: EGLN3
1 Cross references
197 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSONIG00000001505
Gene Symbol: EPAS1
4 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSONIG00000000694
Gene Symbol: ECE1
3 Cross references
229 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSONIG00000010008
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSONIG00000016062
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSONIG00000011716
Gene Symbol: LOC100706592
4 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSONIG00000018701
Gene Symbol: EDNRB
4 Cross references
195 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSONIG00000017651
Gene Symbol: EZH2
4 Cross references
229 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSONIG00000004584
Gene Symbol: EPHB4B
1 Cross references
168 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSONIG00000009358
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).